Apellis Pharma

Forecast & Rating20 analysts currently cover Apellis Pharma, with about 5.0% giving a positive rating — meaning they expect the stock to rise. The average price target is $40.93, about 0.2% downside from the current price of $41.03. Price targets are fairly clustered, pointing to relatively aligned views. Historically, about 60.1% of past price targets were eventually met, which adds credibility. For you, this means most institutions are cautious on Apellis Pharma's outlook. Data as of May 7, 2026; for reference only and not investment advice.